Found: 12
Select item for more details and to access through your institution.
Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Avacopan, a Small‐Molecule Complement C5a Receptor Antagonist, for the Treatment of Antineutrophil Cytoplasmic Autoantibody‐Associated Vasculitis.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 1000, doi. 10.1002/cpdd.1444
- By:
- Publication type:
- Article
Food Effect and Pharmacokinetic Bridging of Avacopan in Caucasian and Japanese Healthy Participants.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 1011, doi. 10.1002/cpdd.1436
- By:
- Publication type:
- Article
Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.
- Published in:
- 2019
- By:
- Publication type:
- Correction Notice
CCR2 antagonism leads to marked reduction in proteinuria and glomerular injury in murine models of focal segmental glomerulosclerosis (FSGS).
- Published in:
- PLoS ONE, 2018, v. 13, n. 3, p. 1, doi. 10.1371/journal.pone.0192405
- By:
- Publication type:
- Article
Pharmacokinetic Evaluation of the CYP3A4 and CYP2C9 Drug‐Drug Interaction of Avacopan in 2 Open‐Label Studies in Healthy Participants.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 5, p. 517, doi. 10.1002/cpdd.1389
- By:
- Publication type:
- Article
Transcription Factor KLF7 Promotes Osteoclast Differentiation by Suppressing HO-1.
- Published in:
- Frontiers in Genetics, 2022, v. 13, p. 1, doi. 10.3389/fgene.2022.798433
- By:
- Publication type:
- Article
Study of Free Radical Fragment Ions Generated from ESI-CID-MSMS Using LTQ and LTQ Orbitrap Mass Spectrometers.
- Published in:
- LC-GC Europe, 2008, v. 21, p. 39
- By:
- Publication type:
- Article
Fast, Sensitive, and Accurate Metabolite Identification Using Multiple Mass Defect Filters and Higher Energy Collisional Dissociation.
- Published in:
- LC-GC Europe, 2008, v. 21, n. 5, p. 12
- By:
- Publication type:
- Article
Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.
- Published in:
- PLoS ONE, 2016, v. 11, n. 10, p. 1, doi. 10.1371/journal.pone.0164646
- By:
- Publication type:
- Article
A phase I thorough QT/QTc study evaluating therapeutic and supratherapeutic doses of avacopan in healthy participants.
- Published in:
- CTS: Clinical & Translational Science, 2024, v. 17, n. 7, p. 1, doi. 10.1111/cts.13878
- By:
- Publication type:
- Article
C5a receptor inhibitor avacopan in immunoglobulin A nephropathy—an open-label pilot study.
- Published in:
- Clinical Kidney Journal, 2022, v. 15, n. 5, p. 922, doi. 10.1093/ckj/sfab294
- By:
- Publication type:
- Article
Investigation of collision-induced dissociations involving odd-electron ion formation under positive electrospray ionization conditions using accurate mass.
- Published in:
- Rapid Communications in Mass Spectrometry: RCM, 2010, v. 24, n. 3, p. 321, doi. 10.1002/rcm.4393
- By:
- Publication type:
- Article